AI Accelerates Longevity and Drug Discovery, While New Hair Loss Treatments Advance in Late-Stage Trials

The news primarily concerns scientific advancements and research, which carry inherent uncertainties but no direct, immediate risks to the general public.

📌 Key developments

• AI Accelerates Longevity and Drug Discovery Insilico Medicine, a biotechnology company using generative artificial intelligence (AI), published a landmark study in Cell on September 17, 2026, introducing an open AI toolkit designed to speed up research and therapeutic development in aging and longevity. This toolkit includes LongevityBench (for evaluating AI in aging biology), Longevity-LLMs (language models trained on aging data), and LongevityClaw (an agentic research platform for identifying therapeutic targets). This follows their September 7, 2026, Nature Biotechnology study, which reported that rentosertib, an AI-discovered and AI-designed drug candidate for idiopathic pulmonary fibrosis (a severe lung scarring disease), reduced biological age—an estimate of how old the body appears based on its health—across six different protein-based aging measures in a Phase IIa clinical trial. This is a significant step in using AI to not only discover new drugs but also to understand and potentially intervene in the aging process, which is a major concern for many, including Iranian readers, due to its links to diseases like heart disease, diabetes, and cancer. The open toolkit means other researchers can use these AI tools. However, while promising, the biological age reduction with rentosertib was observed in a Phase IIa trial for a specific lung disease, not as a general anti-aging treatment. The toolkit is a research tool, not a direct treatment. It does not prove that rentosertib will extend human lifespan or prevent age-related diseases, nor does it mean the AI toolkit will immediately yield new approved longevity treatments. More extensive clinical trials are needed for rentosertib, and the toolkit's long-term impact on drug discovery remains to be seen. The AI toolkit is available for research, and rentosertib is in Phase IIa clinical trials, meaning it's still years away from potential approval and public availability, likely requiring Phase III trials and regulatory review.
• New Topical Treatment for Hair Loss Shows Promise in Late-Stage Trials Clascoterone (brand name Breezula), a topical anti-androgen, has completed Phase III clinical trials for male pattern hair loss, also known as androgenetic alopecia, with promising results. This drug works by directly blocking dihydrotestosterone (DHT), a hormone that contributes to hair loss, at the hair follicle receptors in the scalp, without causing the systemic (body-wide) hormonal effects often associated with oral anti-androgen medications. Two large Phase III trials involving 1,465 patients reported significant improvements in hair count, with a safety profile similar to a placebo (an inactive substance given to a control group). Hair loss is a common and often distressing condition for many, including Iranian readers. This represents a genuinely new mechanism of action—the first in over three decades for male pattern hair loss—offering a potential alternative or addition to existing treatments like minoxidil and finasteride. Its local action makes it particularly significant for women, for whom systemic anti-androgens are often not suitable. However, while Phase III results are strong, clascoterone is not yet approved by any regulatory authority, such as the US Food and Drug Administration (FDA), and is not currently available for prescription. Further regulatory submissions and reviews are underway. It does not guarantee a 'cure' for baldness, nor does it mean it will work for all types of hair loss or for every individual. Long-term efficacy and safety data beyond the trial period are still being gathered. Clascoterone has completed Phase III trials and regulatory submissions are underway. If approved, it could be available in pharmacies in the next few years, but the exact timeline depends on regulatory bodies.
• AI Predicts New Superconducting Materials, Advancing Energy Efficiency Research Researchers, using an artificial intelligence framework, have successfully predicted two previously unknown superconducting materials: YRu₃B₂ and LuRu₃B₂. These materials share a unique atomic structure called a kagome lattice (named after a Japanese basket-weaving pattern), which forces electrons into flat energy bands where quantum forces can dominate, enabling superconductivity—the ability for electricity to flow with zero resistance. Physicists at Rice University then synthesized these materials in the laboratory and confirmed their predicted superconducting properties. Superconductors are crucial for ultra-efficient power grids, quantum computers, and advanced medical imaging because they eliminate energy loss during electricity transmission. Historically, discovering new superconducting materials has been largely trial-and-error. This AI-driven method replaces guesswork with predictive screening, significantly accelerating the discovery process for new materials with desired quantum properties. This could lead to breakthroughs in energy storage (batteries) and industrial catalysts. However, both YRu₃B₂ and LuRu₃B₂ still require extremely cold temperatures to exhibit superconductivity, meaning they are not yet practical for everyday applications like room-temperature superconductors. The true value is in the method of discovery, not the immediate applicability of these specific compounds. It does not guarantee that AI will quickly find room-temperature superconductors, but it provides a powerful new tool for the search. This is a lab discovery and a proof-of-concept for the AI method. Practical applications of room-temperature superconductors are still years, if not decades, away, but this AI tool could shorten that timeline.
• NASA's Roman Space Telescope Activates Advanced Camera for Cosmic Surveys NASA's Nancy Grace Roman Space Telescope has successfully powered up its Wide Field Instrument, a massive 300-megapixel infrared camera, and its Coronagraph Instrument. The Wide Field Instrument is designed to capture enormous stretches of the cosmos with exceptional sharpness, combining a broad view of the sky with fine detail, similar to the Hubble Space Telescope but covering much larger areas. These tests are part of a months-long commissioning process as Roman travels to its destination, the second Lagrange point (L2), about one million miles from Earth. This milestone brings the Roman Space Telescope closer to beginning its science operations in 2027, which will enable scientists to conduct vast surveys of the universe. These observations are expected to provide new insights into exoplanets (planets outside our solar system), dark energy (the mysterious force accelerating the expansion of the universe), and the distribution of matter throughout the cosmos. However, the activation is a commissioning step; the telescope has not yet begun its full science operations or delivered new scientific findings. It does not guarantee specific discoveries, but it confirms the instrument's readiness for its mission. The instruments are powered up and undergoing commissioning. Full science operations are expected to begin in 2027.

💡 Why it matters

These developments highlight a global acceleration in scientific and technological innovation. AI's growing role in hypothesis generation and material design could dramatically shorten discovery timelines and lead to more efficient solutions for critical challenges in health and energy. Advances in medical treatments, even for conditions like hair loss, can significantly improve quality of life for millions worldwide.

🎭 People in the news

• Dr. Alex Zhavoronkov — CEO of Insilico Medicine, a key figure in AI-driven drug discovery and longevity research.
• Dr. Caitlin Andrews — Lead researcher from the University of Sydney on the dietary changes and biological age study.
• Dr. Lynn Petukhova — Senior investigator at NYU Grossman School of Medicine, researching potential links between GLP-1 medications and hair loss.
• Long Ju — Lawrence C. and Sarah W. Biedenharn Associate Professor of Physics at MIT, involved in the graphene superconductivity research.

👀 What to watch

• Further clinical trial results for AI-designed drugs and new hair loss treatments.
• New applications and ethical considerations arising from increasingly specialized AI models.
• Progress in the search for room-temperature superconductors using AI-driven discovery methods.
• Initial scientific data and images from NASA's Roman Space Telescope once it begins full operations.